Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. News
  7. Summary
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EPIZYME, INC. : Change in Directors or Principal Officers (form 8-K)

06/28/2021 | 05:22pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On June 24, 2021, Paolo Tombesi, the Chief Financial Officer of Epizyme, Inc., a Delaware corporation (the "Company"), notified the Company that he will be leaving the Company to pursue other business opportunities, effective July 16, 2021.

The Company's finance function will continue to report to Robert B. Bazemore, the Company's President and Chief Executive Officer. Matthew E. Ros, the Company's Executive Vice President, Chief Strategy and Business Officer, will serve as the Company's principal financial officer, effective July 16, 2021, a role that Mr. Ros has previously served at the Company.

Mr. Ros, 55, has served as the Company's Executive Vice President, Chief Strategy and Business Officer since September 2020, served as the Company's Chief Strategy and Business Officer from September 2018 to September 2020 and served as the Company's Chief Operating Officer from May 2016 to September 2018. Mr. Ros has also served as a member of the board of directors of Cogent Biosciences, Inc., a publicly traded biotechnology company, since July 2019.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about EPIZYME, INC.
09/15EPIZYME : Announces Data from TAZVERIK (Tazemetostat) Clinical Programs to be Presented Du..
AQ
09/14EPIZYME : Announces Data from TAZVERIK« (Tazemetostat) Clinical Programs to be Presented D..
BU
08/23EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
08/20EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/16EPIZYME : FIFTH AMENDMENT TO LEASE (Form 8-K)
PU
08/16EPIZYME, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhib..
AQ
08/10EPIZYME : Morgan Stanley Lowers Epizyme to Underweight From Equal-Weight, Price Target to ..
MT
08/10EPIZYME : HC Wainwright Adjusts Epizyme's Price Target to $15 From $36, Maintains Buy Rati..
MT
08/10EPIZYME : Wedbush Cuts Epizyme's Price Target to $12 From $26, Citing 'Lower-Than-Expected..
MT
08/09EPIZYME : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
More news
Analyst Recommendations on EPIZYME, INC.
More recommendations
Financials (USD)
Sales 2021 53,4 M - -
Net income 2021 -225 M - -
Net cash 2021 96,4 M - -
P/E ratio 2021 -2,44x
Yield 2021 -
Capitalization 545 M 545 M -
EV / Sales 2021 8,41x
EV / Sales 2022 4,48x
Nbr of Employees 304
Free-Float 77,3%
Chart EPIZYME, INC.
Duration : Period :
Epizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPIZYME, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 5,33 $
Average target price 11,14 $
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Grant C. Bogle President, Chief Executive Officer & Director
Matthew E. Ros Chief Financial Officer
David M. Mott Chairman
Shefali Agarwal Executive VP, Chief Medical & Development Officer
Jeffery L. Kutok Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
EPIZYME, INC.-50.92%559
GILEAD SCIENCES, INC.22.19%89 886
BIONTECH SE309.08%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS32.25%67 216
VERTEX PHARMACEUTICALS-22.31%48 018